Navigation Links
Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BR™ Utilizing Circulating Tumor Cells (CTCs)
Date:7/28/2011

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the oncology community, today announced the availability of OncoCEE-BR™ for breast cancer, a test designed to detect circulating tumor cells (CTCs) found in the blood of patients with this disease, and to assess their HER2/neu status by fluorescence in situ hybridization (FISH) performed on the CTCs detected in the blood.  HER2/neu status is diagnostic of a potential response to targeted cancer therapies like Herceptin® and Tykerb®.

OncoCEE-BR™ is intended as an adjunct to current standard testing methods for breast cancer, and may be especially useful in clinical settings where it may not be possible to obtain a tissue biopsy. CTC analysis, including biomarker analysis such as HER2 gene amplification, may provide very important information for the physician in the treatment of a patient's cancer.

The OncoCEE-BR™ test includes: 1) the enumeration of CTCs (their actual number, per an 8 ml blood sample), and 2) the determination of the HER2/neu status of the detected CTCs by FISH.  Clinical studies have demonstrated a poor prognosis for patients with elevated or increasing numbers of CTCs.  The detection of HER2/neu amplification in tissue biopsy samples indicates a patient's eligibility for HER2-targeted therapies like trastuzumab (e.g., Herceptin®).  In the future Biocept intends to add ER/PR status determination to the test, and potentially other biomarkers.   OncoCEE-BR™ is the only commercially available test that combines CTC enumeration with cytogenetic characterization.  It requires a proprietary blood draw tube and sample shipping container, which are provided by Biocept.

The results from an OncoCEE-BR™ test may provide oncologists, pathologists and their patients with a greater understanding of t
'/>"/>

SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Biocept, Inc. Announces CEO and Director Appointments
2. Biocept, Inc. Announces Two New Director Appointments
3. Biocept, Inc. Announces New Director Appointment - September 28, 2010
4. Biocept, Inc. Announces New CFO
5. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
6. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. Anesiva Announces Second Quarter 2008 Financial Results and Update
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... , PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: ... a voluntary recall of five lots and voluntary market withdrawal ... ® . Shire is taking this action because some Daytrana ... meet their release liner removal specification, and as a result, ...
... , , COLUMBIA, Md., Dec. 2 ... it intends to release the results of its fourth quarter and ... Eastern Time (ET). Following the release, at 4:45 p.m. ET ... investors. All interested parties may listen to the call live ...
... , NEW YORK, Dec. 2 Nearly 600 ... to explore novel development approaches and innovative funding strategies at ... FasterCures, the Washington-based center of the Milken Institute, ... needed to turn a scientific discovery into an accessible therapy. ...
Cached Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... South, but the night belongs to the amphibians. In ... humidity and the sounds of wildlife. , The Southeast, ... salamanders, is the center of amphibian biodiversity in our nation. ... their symphonic choruses, the scientists of the U.S. Geological Survey,s ... , Amphibians, which rely on water for part ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... Amlie Perez is preparing to tally the number of ... a row. The objective? To measure the impact of the ... the amphibian populations of southern Quebec. A graduate student ... visit more than 50 swamps and lakes. Last year she ...
... at The University of Western Ontario finds the sauces you ... unforeseen health benefits. The research, led by Western biology ... be more than just tasty sauces they can also ... co-authored by Mark Bernards and Christopher Guglielmo in Western,s department ...
... HOUSTON , March 23 Today, Texas ... the TMS320C5515 Fingerprint Development Kit, a complete signal chain solution ... fingerprint biometric features in reduced time to market.  This robust ... digital signal processor (DSP), two widely-used sensor types (swipe and ...
Cached Biology News:Counting frogs: Why monitoring our amphibian populations is important 2Spice up your health this barbecue season 2Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments' comprehensive, low cost fingerprint development kit 2Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments' comprehensive, low cost fingerprint development kit 3Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments' comprehensive, low cost fingerprint development kit 4Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments' comprehensive, low cost fingerprint development kit 5Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments' comprehensive, low cost fingerprint development kit 6
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Proliferin (C-14)...
... of your ValveBank system! Program your ... Macintosh computer using graphic 'click-and-drag' timebars. Save ... out program listings, then download your programs ... step., EasyCode is used for programming before ...
Biology Products: